Milestones 2017

Important Scientificmilestones in 2017:

  • Established new technology in lab; the Nano String machine
  • Established new method in lab; drug screen of the patient’s own cancer cells
  • Established cooperation with SAGE Bionetwork (

Doctoral degrees in 2017:

  • Lars Thomas Seeberg (Wiedswang group)

Most important funding sources in 2017:

  • Norwegian Research council (FRIPRO)
  • Stiftelsen (The foundation) Kristian Gerhard Jebsen
  • Norwegian Cancer Society
  • South-Eastern Norway Regional Health Authority
  • University of Oslo, Norway
  • OUS- Radium hospital endowments
  • EU founding (by an International network, Wiedswang – Naume group)

Most important application activity (for external funding) in 2017:

  • Stiftelsen (The foundation) Kristian Gerhard Jebsen – we have had 4 years of funding 2013-2017, in 2017 we applied for extension 2 years, application granted
  • Application to Norwegian Cancer Society, multicenter study in cooperation with the Norwegian Cancer Registry, biomarkers in colorectal cancer
  • Application to South-Eastern Norway Regional Health Authority
  • Application to Norwegian Cancer Society

Awards, distinctions etc. in 2017:

Excellent publication award in OUS (LT Seeberg) 

Innovations / Innovation projects  / Patents in 2017:

  • Establishing cell culture (organoid models) for ex vivo drug sensitivity testing of living cancer cells from resected liver metastases (recently chosen by NATURE as “Method of the year 2017”)
  • Nano string machine / technology established in lab
  • Patent “Methods and biomarkers for analyses of colorectal cancer 
    Publication number: 20170038386 Publication date: February 9, 2017
    Inventors: Ragnhild A. Lothe, Jarle Bruun, Matthias Kolberg, Rolf Inge Skotheim, Guro Elisabeth Lind, Arild Nesbakken

Short self-assessment of the group’s strengths and improvement areas/points


  • A quite unique – large, consecutive, population based series of colorectal cancer patients (n=3400) with comprehensive, high quality clinical dataset.A large biobank of primary tumors (TMA of 2000 formalin fixed tumors, fresh frozen tissue 950 patients), liquid biopsy before operation of 500 pts, and from 300 patients at follow-up (Nesbakken)
  • Blood, bone marrow, plasma, biopsies, cells from several thousand different cancer patients (Wiedswang)
  • Strong multidisciplinary cooperation
  • “All” lab methods for molecular analyses well established in own lab


  • Stronger international cooperation
  • Few surgeons are involved in the research; problems to recruit new, dedicated researchers who can substitute the present senior surgical researchers
  • We may have to concentrate efforts on fewer research topics in order to reach the absolute top international level

Popular scientific contributions (newspaper/magazine chronicles, blog-posts, open lectures etc.):

  • Website
  • Portrait of B Naume in “Dagens medisin” as the only Norwegain speaker at ASCO
  • Web-article,

3 most important publications from the two last years (2017 and 2016):

Year 2017:

  • Survival impact of primary tumor lymph node status and circulating tumor cells in pts with colorectal liver metastases. Seeberg LT, …Borgen E, Naume B, Wiedswang G. Ann Surg Onc 2017 aug ; 24(8):2113-2121
  • Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J (2017). Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.Ann Oncol, 28 (5), 1023-1031
  • Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA (2017) 
    Multilevel genomics of colorectal cancers with microsatellite instability - clinical impact of JAK1 mutations and consensus molecular subtype 1. Genome Med, 9 (1), 46

Year 2016:

  • Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, Fessler, E, Medema JP, Boot A, Morreau H, van Wezel T, Liefers GJ, Lothe RA, Danielsen SA, Sveen A, Nesbakken A, Zlobec I, Lugli A, Koelzer, VH, Berger MD, Castellví-Bel S, Muñoz J; Epicolon consortium, de Bruyn M, Nijman HW, Novelli M, Lawson K, Oukrif D, Frangou E, Dutton P, Tejpar S, Delorenzi M, Kerr R, Kerr D, Tomlinson I, Church DN. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):207-216
  • Boye K, Jacob H, Frikstad KA, Nesland JM, Maelandsmo GM, Dahl O, Nesbakken A, Flatmark K. Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy. Cancer Med. 2016 Aug;5(8):1840-9.
  • Rønning B, Wyller TB, Nesbakken A, Skovlund E, Jordhøy MS, Bakka A, Rostoft S. Quality of life in older and frail patients after surgery for colorectal cancer- A follow-up study. J Geriatr Oncol. 2016 May;7(3):195-200


Page visits: 1102